In the phase III SOLO-1 trial, first-line treatment with the PARP inhibitor olaparib extended progression-free survival among patients with BRCA-mutated ovarian cancer. In a study presented at the 2022 ASCO Annual Meeting, Eskander et al evaluated real-world characteristics, treatment patterns, and outcomes among patients with newly diagnosed, BRCA-mutated ovarian cancer receiving treatment with olaparib.
